<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952314</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-URO-2012-03</org_study_id>
    <secondary_id>SNUBH-URO-2012-03-MET</secondary_id>
    <nct_id>NCT01952314</nct_id>
  </id_info>
  <brief_title>Medical Expulsive Therapy for Ureter Stone Using Naftopidil</brief_title>
  <official_title>Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate whether naftopidil is effective or not for the spontaneous
      passage of ureteral stones with sizes of 3 to 10 mm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Enrollment

             1. patients with ureteral stones of sizes from 3 to 10 mm

             2. patients aged more than 18 years

        2. Randomization

             1. naftopidil 75 mg qd for 14 days or placebo

             2. Standard treatment with pain-killers were also applied.(aceclofenac)

        3. Follow-up for 28 days

             1. We confirm the stone free status by CT or X-ray films at 14th and 28th days.

             2. Rates of active treatment will be also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone-free rate at 14th day of study</measure>
    <time_frame>14th day</time_frame>
    <description>Rate of stone-free as confirmed by non-contrast CT, intravenous urography or simple x-ray (only for radio-opaque stone)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stone-free rate at 28th day of study</measure>
    <time_frame>28th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration to stone passage within 28days of study</measure>
    <time_frame>for 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of analgesics used for 28 days of study</measure>
    <time_frame>for 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of active treatment</measure>
    <time_frame>for 28 days</time_frame>
    <description>Active treatments include shock-wave lithotripsy, ureteroscopic ureterolithotomy, ureteral stenting or other surgical treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Ureter Stones</condition>
  <arm_group>
    <arm_group_label>Control groups with only analgesics</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control groups will receive only analgesics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftopidil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This interventional group will receive analgesics and naftopidil 75mg po qd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftopidil 75mg</intervention_name>
    <description>naftopidil 75mg 1T qd hs</description>
    <arm_group_label>Naftopidil</arm_group_label>
    <other_name>Flivas(TM) in South Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Naftopidil</intervention_name>
    <description>Placebo 1T qd hs</description>
    <arm_group_label>Control groups with only analgesics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand</description>
    <arm_group_label>Control groups with only analgesics</arm_group_label>
    <arm_group_label>Naftopidil</arm_group_label>
    <other_name>Pain control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 20 years

          -  single 3 to 10 mm ureter stone (longest diameter)

        Exclusion Criteria:

          -  Presence of multiple ureter stones

          -  Renal insufficiency (serum Cr &gt; 1.4 mg/dL)

          -  Febrile urinary tract infections(fever &gt; 38Â°C, evidence of urinary infection)

          -  pregnancy or breast feeding

          -  solitary kidney

          -  hypersensitivity to naftopidil

          -  current use of any alpha-blocker, calcium-channel blocker, corticosteroid (within 4
             weeks)

          -  moderate or severe cardiovascular or cerebrovascular disease

          -  hepatic dysfunction (&gt;2 x normal upper limit)

          -  significant active medical illness which in the opinion of the investigator would
             preclude protocol treatment

          -  Genetic disorder such as Galactose intolerance, Lapp Lactase deficiency,
             Glucose-Galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Wook Jeong, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Donguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Kyunggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggi</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Chang Wook Jeong</investigator_full_name>
    <investigator_title>M.D, Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

